What side effects are associated with this type of intervention?

The most common treatments for prostate cancer, particularly those involving androgen deprivation therapy (ADT), include medications like abiraterone, enzalutamide, and docetaxel. Known side effects of ADT and these medications can include hot flashes, decreased libido, fatigue, and osteoporosis. Abiraterone may cause hypertension and hypokalemia, while enzalutamide can lead to fatigue and hypertension. Docetaxel, a chemotherapy agent, is associated with myelosuppression, neuropathy, and gastrointestinal symptoms. These side effects can significantly impact the quality of life, making supportive resources like the STAND-T digital platform valuable for managing symptoms and improving patient outcomes.

What prior FDA approvals exist?

FDA-approved treatments for prostate cancer include a variety of systemic therapies and targeted treatments. Notably, lutetium Lu 177 vipivotide tetraxetan has been approved for PSMA-positive metastatic CRPC, and cabazitaxel has shown efficacy in patients who have progressed on docetaxel. While these treatments focus on direct therapeutic effects, the STAND-T trial explores a digital platform aimed at providing educational and supportive resources to men undergoing androgen deprivation therapy. This approach is unique in its focus on leveraging technology to improve health outcomes and promote equity, rather than direct pharmacological intervention.

What other types of research exist?

Promising novel alternatives to the STAND-T digital platform for prostate cancer patients in 2024 include: 1) Lutetium-177-PSMA-617, a radioligand therapy for metastatic castration-resistant prostate cancer, 2) Pembrolizumab and Dostarlimab for patients with dMMR or high TMB metastatic CRPC, 3) Combined ADT with newer agents like darolutamide or abiraterone for high-risk/high-volume metastatic disease, and 4) Prostate-specific PET radiotracers for better selection of patients for salvage radiotherapy.

← Back to Search

Digital Health Platform for Prostate Cancer

N/A

Waitlist Available

Led By Stacey Kenfield, DSc

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >18 years

Ability of individual or legal guardian/representative to understand an informed consent document and the willingness to sign it

Must not have

Planned surgery/chemotherapy/immunotherapy/parp inhibitor treatment during the study period

Unable to read/speak English

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial studies a digital platform called STAND-T, which helps men undergoing treatment for prostate cancer by providing health information and sending messages periodically. The goal is to improve their health and manage symptoms better.

Who is the study for?

This trial is for men over 18 with prostate cancer who are on or planning to start anti-androgen therapy. They should have a life expectancy of at least 6 months, understand the study and consent to participate. Men who exercise very little and haven't had recent dietary or exercise counseling can join.

What is being tested?

The STAND-T digital platform is being tested in this trial. It's designed to provide health information and resources specifically for men undergoing androgen deprivation therapy for prostate cancer, aiming to improve their health outcomes and promote equity.

What are the potential side effects?

Since the intervention involves a digital platform providing information rather than a medical treatment, traditional side effects like those seen with medications are not expected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I can understand and am willing to sign the informed consent document.

Select...

I have been diagnosed with prostate adenocarcinoma.

Select...

I am currently on or planning to start hormone therapy for cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am scheduled for surgery or cancer treatment during the study.

Select...

I cannot read or speak English.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Completion rate

Secondary study objectives

Change in the proportion of men who were Extremely Satisfied/Satisfied

Participants reported satisfaction level

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Health services research (STAND-T, text messages)Experimental Treatment3 Interventions

Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.

0 / 6Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for prostate cancer include androgen deprivation therapy (ADT) and immunotherapy. ADT lowers serum testosterone levels, reducing the growth stimulus for prostate cancer cells. Immunotherapy, such as sipuleucel-T, stimulates the patient's immune system to target and destroy cancer cells. Understanding these mechanisms helps patients grasp how treatments control cancer progression and manage symptoms, facilitating informed decision-making with their healthcare providers.

Choosing the right treatment for patients with psoriatic arthritis.Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.